Nova Publishers
My Account Nova Publishers Shopping Cart
HomeBooksSeriesJournalsReference CollectionseBooksInformationSalesImprintsFor Authors
            
  Top » Catalog » Books » My Account  |  Cart Contents  |  Checkout   
Quick Find
  
Use keywords to find the product you are looking for.
Advanced Search
What's New? more
Doxycycline: Medical Uses and Effects
$82.00
Shopping Cart more
0 items
Information
Shipping & Returns
Privacy Notice
Conditions of Use
Contact Us
Notifications more
NotificationsNotify me of updates to Safety Efforts in Pediatric Drug Development
Tell A Friend
 
Tell someone you know about this product.
Safety Efforts in Pediatric Drug Development
Retail Price: $120.00
10% Online Discount
You Pay:

$108.00
Editors: Conor D. Byrne
Book Description:
This book focuses on the safety efforts being implemented in pediatric drug development. Although children suffer from many of the same diseases as adults and are often treated with the same drugs, only about one-third of the drugs that are prescribed for children have been studied and labeled for pediatric use. This has placed children taking drugs for which there have not been adequate pediatric drug studies at risk of being exposed to ineffective treatment or receiving incorrect dosing. In order to encourage the study of more drugs for pediatric use, Congress passed the Best Pharmaceuticals for Children Act (BPCA) in 2002 to provide marketing incentives to drug manufacturers for conducting pediatric drug studies. Drug manufacturers may obtain six months of additional market exclusivity for drugs on which they have conducted pediatric studies in accordance with pertinent law and regulations. This book also evaluates the impact of BPCA on labeling drugs for pediatric use and the process by which the labeling was changed, and illustrates the range of diseases treated by the drugs studied under BPCA. Additionally this book provides guidance on the role and timing of animal studies in the nonclinical safety evaluation of therapeutics intended for the treatment of pediatric patients. The guidance discusses some conditions under which juvenile animals can be meaningful predictors of toxicity in pediatric patients and makes recommendations on nonclinical testing.

This book consists of public documents which have been located, gathered, combined, reformatted, and enhanced with a subject index, selectively edited and bound to provide easy access.

We’ve partnered with Copyright Clearance Center to make it easy for you to request permissions to reuse Nova content.
For more information, click here or click the "Get Permission" button below to link directly to this book on Copyright Clearance Center's website.


Table of Contents:
Preface

FDA's Authority to Ensure that Drugs Prescribed to Children Are Safe and Effective (Susan Thaul), pp. 1-30

Guidance for Industry Nonclinical Safety Evaluation of Pediatric Drug Products (U.S. Dept. of Health and Human Services, Food and Drug Administration, Centre for Drug Evaluation and Research (CDER), pp. 31-58

Pediatric Drug Research: Studies Conducted under Best Pharmaceuticals for Children Act (GAO), pp. 59-108

Pediatric Drug Research: The Study and Labeling of Drugs for Pediatric Use under the Best Pharmaceuticals for Children Act (GAO), pp. 109-124

Index, pp. 125

   Series:
      Pharmacology - Research, Safety Testing and Regulation
   Binding: Hardcover
   Pub. Date: 2010 1st Quarter
   ISBN: 978-1-60741-565-7
   Status: AV
  
Status Code Description
AN Announcing
FM Formatting
PP Page Proofs
FP Final Production
EP Editorial Production
PR At Prepress
AP At Press
AV Available
  
Special Focus Titles
01.Violent Communication and Bullying in Early Childhood Education
02.Cultural Considerations in Intervention with Women and Children Exposed to Intimate Partner Violence
03.Chronic Disease and Disability: The Pediatric Lung
04.Fruit and Vegetable Consumption and Health: New Research
05.Fire and the Sword: Understanding the Impact and Challenge of Organized Islamism. Volume 2

Nova Science Publishers
© Copyright 2004 - 2020

Safety Efforts in Pediatric Drug Development